The Lancet Infectious Diseases

The Lancet Infectious Diseases is a monthly peer-reviewed medical journal published by Elsevier as part of the Lancet family, founded in 2001 and covering clinical infectious diseases and global health, with a 2025 Journal Impact Factor of 29.4《柳叶刀：感染病学》是由爱思唯尔（Elsevier）出版、隶属柳叶刀家族的月刊同行评审医学期刊，2001 年创刊，聚焦临床感染病学与全球健康，2025 年影响因子为 29.4。

Scope

• It serves as an authoritative forum for key opinion leaders across medicine, government and health systems to influence clinical practice and explore global policy, and as a global leader it delivers original research, expert review, candid commentary and breaking news该刊是供医学、政府与卫生系统各界意见领袖影响临床实践、探讨全球政策的权威论坛，并作为全球领军刊物提供原创研究、专家综述、坦率评论与即时资讯。
• Its coverage spans antimicrobial therapy and immunization as well as bacterial, viral, fungal and parasitic infections其报道范围涵盖抗感染治疗与免疫接种，以及细菌、病毒、真菌和寄生虫感染。^[1]
• It also addresses emerging infections, AIDS, malaria, tuberculosis and mycobacterial infections该刊也关注新发感染、艾滋病、疟疾、结核病与分枝杆菌感染。
• Infection control and infectious disease epidemiology form further core topics, alongside neglected tropical diseases and travel medicine感染控制与感染病流行病学构成另一类核心主题，被忽视的热带病与旅游医学也在其列。
• Article types include original Articles, Review, Historical Review, Personal View, Comment, Correspondence and news文章类型包括原创论文、综述、历史评论、个人观点、评论、通讯与资讯。
• It is published monthly and releases Online First articles ahead of the print issue该刊按月出版，并在纸本刊期之前先行在线发布（Online First）文章。

History

• The journal was launched in 2001 as a specialty title within the Lancet family of journals该刊于 2001 年作为柳叶刀期刊家族的专科子刊创刊。
• It is one of the Lancet specialty journals, alongside titles such as The Lancet Oncology, The Lancet Neurology and The Lancet Public Health它是柳叶刀系列专科期刊之一，与（The Lancet Oncology）、（The Lancet Neurology）与（The Lancet Public Health）等刊物并列。
• It is published by Elsevier on behalf of the Lancet Group and maintains an editorial office in London该刊由爱思唯尔（Elsevier）代表柳叶刀集团出版，并在伦敦设有编辑部。
• It has become the leading journal in the field of infectious diseases worldwide该刊已成为全球感染病学领域的领军期刊。
• Its 2025 Journal Impact Factor is 29.4, ranking first among 141 infectious diseases journals in the SCIE edition of the Journal Citation Reports其 2025 年影响因子为 29.4，在期刊引证报告的 SCIE 版 141 种感染病学期刊中排名第一。
• Its impact factor reached a high of 71.421 in 2022 before settling at 31.0 in 2024, reflecting its role during the COVID-19 pandemic其影响因子在 2022 年达到 71.421 的高点，2024 年回落至 31.0，反映其在新冠疫情期间的作用。^[2]

Editors

• The editor-in-chief is Ursula Hofer, who joined the journal in 2022 after almost a decade at Springer Nature现任主编为 Ursula Hofer，她于 2022 年加入该刊，此前在施普林格·自然（Springer Nature）任职近十年。
• She previously served as chief editor of Nature Reviews Microbiology and was part of the launch team of Nature Reviews Disease Primers她此前担任（Nature Reviews Microbiology）主编，并参与（Nature Reviews Disease Primers）的创刊团队。
• She received her medical degree from the University of Bern in Switzerland她的医学学位得自瑞士的伯尔尼大学（University of Bern）。
• The deputy editor is Marco De Ambrogi, and the senior editors are Syeda Saleha Hassan and Phoebe Hall副编辑为 Marco De Ambrogi，高级编辑为 Syeda Saleha Hassan 与 Phoebe Hall。
• All research and review articles undergo peer review before publication所有研究与综述文章在发表前均经过同行评审。
• The editorial team also produces a podcast, The Lancet Infectious Diseases in conversation with, featuring authors and experts该刊编辑团队还制作播客（The Lancet Infectious Diseases in conversation with），邀请作者与专家参与。